The Hong Kong Association of Pharmaceutical Industry organized a successful briefing session for its Regulatory Intelligence Survey, attracting over 50 members to join the event.
Asia Summit on Global Health 2022 It is a great privilege for The Hong Kong Association of the Pharmaceutical Industry to join the Asia Summit on Global Health 2022 organized […]
To ensure members have a thorough understanding of the relevant laws, regulations and Codes regarding medicinal material communicating to the public via different mediums, the HKAPI organises an event with law enforcement authorities and experts to explain the law and its enforcement.
The High-Level Steering Committee on Antimicrobial Resistance was set up in 2016 to call for collaboration, synergy and cross-fertilisation of all professional sectors under the "One Health" framework in response to AMR. Ms. Sabrina Chan, the Senior Executive Director of HKAPI has been a member of the Steering Committee since the establishment of the Committee.
The Greater Bay Area development has taken centre stage in Hong Kong Policy Address 2020. To facilitate members taking business opportunities in GBA, HKAPI jointly organized a virtual training with the Shenzhen Hospital Manager Association in November and December 2020.
On December 18, 2019, around 70 members from the regulatory affairs and pharmacovigilance department attended the New Product submission and Best Practice Workshop held at HKU.
About 60 members, non-members and academics turned up for Product Life Cycle Management from Regulatory Perspective and Best Practice Workshop jointly organized by The University of Hong Kong and HKAPI.
On 14 December 2018, a joint briefing session between the Drug Office and HKAPI was held at the Public Health Laboratory Centre in Kowloon. It was overwhelmingly attended by about 90 members, with the majority being Regulatory Affairs staff.